Mirum Pharmaceuticals, Inc. $MIRM Stock: Candriam S.C.A. Decreases Position

Key Points

• Candriam S.C.A. reduced its Mirum Pharmaceuticals stake by 4.4%, selling 16,510 shares; it retained 359,633 shares, worth about $30.9 million.
• Mirum’s quarterly revenue rose 39.6% year over year to $185.72 million, topping estimates, but its $0.87-per-share loss was wider than the expected $0.49 loss.
• Analyst views were broadly positive, with a “Moderate Buy” consensus and an average $154.94 price target, though some firms lowered earnings forecasts.

Candriam S.C.A. cut its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 4.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 359,633 shares of the company's stock after selling 16,510 shares during the period. Candriam S.C.A. owned approximately 0.55% of Mirum Pharmaceuticals worth $30,854,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in MIRM. BlackRock Inc. purchased a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter worth approximately $513,945,000. Emerald Advisers LLC boosted its position in shares of Mirum Pharmaceuticals by 8.2% during the 1st quarter. Emerald Advisers LLC now owns 397,263 shares of the company's stock valued at $36,699,000 after acquiring an additional 30,129 shares during the last quarter. Jupiter Topco LLC bought a new position in shares of Mirum Pharmaceuticals during the 2nd quarter valued at approximately $691,672,000. Man Group plc purchased a new position in shares of Mirum Pharmaceuticals in the second quarter valued at $4,353,000. Finally, Rice Hall James & Associates LLC purchased a new position in shares of Mirum Pharmaceuticals in the second quarter valued at $12,956,000.

Mirum Pharmaceuticals Price Performance

Shares of MIRM opened at $93.72 on Monday. The company has a quick ratio of 1.98, a current ratio of 2.07 and a debt-to-equity ratio of 1.28. The business has a fifty day moving average of $89.29 and a 200 day moving average of $98.46. The company has a market cap of $6.12 billion, a PE ratio of -6.06 and a beta of 0.75. Mirum Pharmaceuticals, Inc. has a 52-week low of $63.23 and a 52-week high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.38). Mirum Pharmaceuticals had a negative net margin of 134.75% and a negative return on equity of 97.25%. The firm had revenue of $185.72 million for the quarter, compared to the consensus estimate of $178.07 million. During the same quarter last year, the firm earned $0.05 EPS. The company's revenue was up 39.6% on a year-over-year basis. On average, sell-side analysts expect that Mirum Pharmaceuticals, Inc. will post -1.47 EPS for the current year.

Key Headlines Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained its “Buy” rating and $202 price target, while still projecting a path to higher earnings over the longer term; its FY2030 EPS estimate rose to $10.76 from $10.03. HC Wainwright estimates
• Positive Sentiment: Mirum’s latest quarter showed revenue up 39.6% year over year to $185.72 million, ahead of analyst expectations. The stock also moved above its 50-day moving average after the earnings release, a potentially supportive technical signal. Stock crosses 50-day moving average
• Neutral Sentiment: Leerink Partners lowered its price target to $140 from $154 but kept an “Outperform” rating. That reflects reduced upside expectations while retaining a positive view of the shares. Leerink Partners rating
• Negative Sentiment: HC Wainwright substantially cut EPS estimates for 2026 and 2027, shifting its FY2027 forecast from a $1.16 profit to a $1.28 loss. It also reduced its FY2028 estimate from $5.38 to $2.64 and FY2029 from $7.21 to $6.85, indicating weaker expected earnings in the coming years despite the maintained Buy rating. HC Wainwright revised EPS estimates
• Negative Sentiment: Quarterly EPS was a loss of $0.87, wider than the expected $0.49 loss. The earnings shortfall tempers the revenue beat and may weigh on investor sentiment. Earnings and stock outlook
• Negative Sentiment: CEO Christopher Peetz sold 20,000 shares worth $1.8 million. The sale was made under a pre-arranged Rule 10b5-1 trading plan, which may soften its significance but can still draw investor attention. CEO share sale

Insider Buying and Selling

In related news, SVP Jolanda Howe sold 40,000 shares of the company's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $100.00, for a total transaction of $4,000,000.00. Following the transaction, the senior vice president directly owned 1,274 shares in the company, valued at approximately $127,400. This represents a 96.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Christopher Peetz sold 30,000 shares of the stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $98.68, for a total transaction of $2,960,400.00. Following the completion of the sale, the chief executive officer directly owned 194,440 shares in the company, valued at $19,187,339.20. This trade represents a 13.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 96,659 shares of company stock valued at $9,425,700. Company insiders own 8.32% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on MIRM. HC Wainwright boosted their price target on shares of Mirum Pharmaceuticals from $200.00 to $202.00 and gave the stock a "buy" rating in a research report on Wednesday, November 4th. Evercore reiterated an "outperform" rating and set a $146.00 price objective on shares of Mirum Pharmaceuticals in a research report on Tuesday, October 13th. Wall Street Zen cut shares of Mirum Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Sunday, September 6th. Morgan Stanley lifted their price objective on shares of Mirum Pharmaceuticals from $137.00 to $152.00 and gave the stock an "overweight" rating in a research note on Monday, October 12th. Finally, Raymond James Financial restated a "strong-buy" rating and issued a $189.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Mirum Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $154.94.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options.

Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.

Mirum serves patients in the United States and other markets, including parts of Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.